Dr. Peyton Greenside is the Co-founder and Chief Executive Officer of BigHat Biosciences, a biotechnology company pioneering the integration of machine learning and synthetic biology to accelerate the design of next-generation antibody therapeutics. She brings a deep background at the intersection of computational biology, machine learning, and biology, with prior experience as an inaugural Schmidt Science Fellow at the Broad Institute and as a scientific co-founder of Valis Genomics. Peyton holds a Ph.D. in biomedical informatics from Stanford University, an M.Phil. from the University of Cambridge as a Herchel Smith Scholar, and a B.A. from Harvard University.
Earlier this year, Peyton transitioned from Chief Scientific Officer to CEO, where she now drives BigHat’s overall vision, strategy, and growth. She oversees R&D, business development, operations, and culture, ensuring alignment across a fast-growing, interdisciplinary team. Her leadership has been central to raising more than $140M in venture funding and establishing strategic partnerships with leading pharmaceutical companies including Amgen, Merck, AbbVie, Johnson & Johnson, and Eli Lilly.
Peyton has been a trailblazer in applying AI/ML to biologics, advancing BigHat’s proprietary Milliner platform to deliver higher-quality therapeutics faster and more efficiently. Under her stewardship, BigHat is expanding its internal therapeutic pipeline and broadening its impact through industry collaborations. Recognized as both a scientist and a leader, Peyton continues to shape the future of drug discovery by combining scientific rigor with strategic execution and a mission-driven approach to improving patient outcomes.